Aubagio

Chemical Nameteriflunomide
Dosage FormTablet (oral; 7 mg, 14 mg)
Drug ClassInhibitors
SystemNervous
CompanyGenzyme Corporation
Approval Year2012

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Last updated on 5/2/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Aubagio (teriflunomide) Prescribing Information.2022Genzyme Corporation, Cambridge, MA